Showing results (101-110 of 290) with videos related to
Sort By:
Pageof 29
The Oncologist|April 9, 2014
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practiceNeil Vasan, Roman Yelensky, Kai Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerLecia V Sequist, Benjamin Besse, Thomas J Lynch, et al.Cancer|June 20, 2007
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancerDaniel T Milton, Gregory J Riely, Christopher G Azzoli, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancerKatharine A Price, Christopher G Azzoli, Lee M Krug, et al.Cancer Chemotherapy and Pharmacology|April 5, 2011
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusionPaul K Paik, Leonard P James, Gregory J Riely, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trialPasi A Jänne, Xiaofei Wang, Mark A Socinski, et al.Case Reports in Oncology|November 20, 2014
A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to CrizotinibJon H Chung, Siraj M Ali, Jenni Davis, et al.The Oncologist|February 15, 2017
Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary CancersBenjamin A Weinberg, Kyle Gowen, Thomas K Lee, et al.The Oncologist|May 7, 2016
Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical TrialsJames H Suh, Adrienne Johnson, Lee Albacker, et al.Oncotarget|June 17, 2015
Identification and characterization of RET fusions in advanced colorectal cancerAnne-France Le Rolle, Samuel J Klempner, Christopher R Garrett, et al.Pageof 29